UT Health San Antonio
medical oncologist specializing in breast cancer and cancer genetics
Talks (36)
Air Time: 181:04:17
chemo prevention and breast cancer
Dec 31
treating micromets in breast cancer
Dec 31
radiosensitization in breast cancer
Dec 31
cdk46 in first line mbc and os
Dec 31
benefit of cdk46 in subtypes of er+
Dec 31
dato dxd in HR pos MBC
Nov 19
capivasertib in HR pos MBC
Nov 19
adj therapy in high risk her2 pos BC
Nov 19
should we use IO in HR pos early BC?
Nov 19
immunotherapy in HR+ early BC
Nov 19
Second line HER2 pos MBC
Oct 01
First line HER2 pos MBC
Oct 01
secretory breast cancer
Oct 01
Second line therapy in metastatic TNBC
Oct 01
her2 mutations in breast cancer
Aug 15
first line therapy in met TNBC
Jul 31
endocrine resistance.
Jul 31
second line therapy in HR pos MBC
Jul 31
therapy selections for neo HR pos BC
Jul 31
neo adjuvant therapy in HR pos EBC
Jul 31
pik3ca mutations in breast cancer.
Jun 29
adj therapy for low risk her2 BC
Jun 29
neo adjuvant therapy for her2 pos BC
Jun 29
genetic testing for breast cancer
Jun 20
defining triple negative breast cancer
May 30
use of CDK4/6 inhibitors in early breast
May 27
